https://doi.org/10.4081/reumatismo.2016.873

New approved drugs for psoriatic arthritis

Vol. 68 No. 2 (2016)
Submitted: 22 February 2016
Accepted: 13 July 2016
Published: 9 September 2016
Psoriatic arthritis, treatment, ustekinumab, secukinumab, apremilast.
Abstract Views: 2864
PDF: 2130
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

F.M. Perrotta
Academic Rheumatology Unit, Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
E. Lubrano
enniolubrano@hotmail.com
Academic Rheumatology Unit, Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Psoriatic arthritis (PsA) is a chronic inflammatory disease that possibly leads to structural damage and to a reduction of joint function and poor quality of life. Treatment of PsA has changed since its introduction of anti- TNF drugs, which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. However, recently, the discovery of new pathogenic mechanisms have made possible the development of new molecules that target pro-inflammatory cytokines involved in skin, joint and entheseal inflammation. New drugs like ustekinumab, secukinumab and apremilast inhibit interleukin axis and intracellular pathways and showed their efficacy and safety in randomized clinical trials. These drugs have been recently approved for the treatment of PsA and included in the new EULAR and GRAPPA treatment recommendations. The aim of this paper is to briefly review the clinical trials that led to their approval for PsA.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
E. Lubrano, Academic Rheumatology Unit, Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso
Aggregate Professor

How to Cite

Perrotta, F., & Lubrano, E. (2016). New approved drugs for psoriatic arthritis. Reumatismo, 68(2), 57–64. https://doi.org/10.4081/reumatismo.2016.873

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

<< < 45 46 47 48 49 50 51 52 53 54 > >> 

You may also start an advanced similarity search for this article.